A Phase 4 interventional study of CsA+Rapamune+CS and CsA+MMF+CS in Inflammation, sponsored by Pfizer. Completed at 4 sites in Iran, Islamic Republic of. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-12-12.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Inflammation with a site in Iran, Islamic Republic of — 1 open to participants now, 3 under way, none of them phase 3. Inflammation · Iran, Islamic Republic of.
Among the 24 studies in Inflammation with a site in Iran, Islamic Republic of, this one has the largest enrollment of the 22 interventional ones that give a count, is the only one that started in 2006, is one of 4 in phase 4, and was the 5th registered.
3,541 studies on the registry are indexed under Inflammation; 646 are open to participants now.
Browse Inflammation studies →1 of the 24 studies in Inflammation with a site in Iran, Islamic Republic of is open now. Recruiting first, the newest first:
National Nutrition and Food Technology Institute · Sites in Iran, Islamic Republic of
Ages 18–40 · Women only
A study can be open while its sites in Iran, Islamic Republic of have not opened yet or have stopped. Only those recruiting at a site in Iran, Islamic Republic of →
Of the 461 Inflammation studies recruiting now, 174 (38%) set no upper age limit and 206 (45%) stop at 75 or younger; 56 take children under 18; 165 take healthy volunteers.
This study: 13 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 245 is above the median of 50 across 2,582 interventional studies indexed under Inflammation.
Median enrollment 80 across the 22 interventional studies. Of the 15 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 24 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 3 studies filed under Inflammation — fewer than ten, so there is no comparison to draw.
1 of the studies in Inflammation with a site in Iran, Islamic Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06758752Fasa University of Medical SciencesA Herbal Compound for Eczema | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Inflammation with a site in Iran, Islamic Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the safety and efficacy of cyclosporine (CsA) + mycophenolate mofetil (MMF) + corticosteroids © to CsA + Rapamune + Cs with CsA elimination in the Rapamune arm with the introduction of MMF in de novo renal allograft recipients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CsA+Rapamune+CS
Drug: CsA+MMF+CS
Drug pages: Cyclosporine · Sirolimus
Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
Drug pages: Cyclosporine · Mycophenolic Acid
The control arm is the standard local practice (official protocol) in Iran: Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS.
Incidence of Efficacy Failure
Efficacy failure was defined as first occurrence of either biopsy confirmed acute rejection, graft loss or death within 12 months of post-transplantation. Percentage of participants with efficacy failure was reported.
Time frame: Baseline up to Month 12
Serum Creatinine Level
Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 milligram per deciliter (mg/dL) for females and 0.6 to 1.2 mg/dL for males; however, the normal values are age-dependent as elderly patients typically have smaller muscle mass.
Time frame: Month 3, 6, 12
Creatinine Clearance
Creatinine clearance (CCr) is a measure of kidney function. CCr is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Normal values for healthy, young males are in the range of 100-135 millimeters per minute (mL/min) and for females, 90-125 mL/min. Creatinine clearance decreases with age. A low creatinine clearance rate indicates poor kidney function.
Time frame: Month 3, 6, 12
Glomerular Filtration Rate (GFR) by Nankivell Method
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR was calculated using the Nankivell formula. GFR by Nankivell equation= (6.7 per serum creatinine) plus (0.25\*body weight) minus (0.5\*serum urea) minus (100 per height square) plus (35 for male or 25 for female). A normal GFR is greater than (\>)90 mL/min per 1.73 m\^2 \[mL/min/1.73 m\^2\], although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (\<)15 mL/min/1.73 m\^2 indicated kidney failure.
Time frame: Month 3, 6, 12
Incidence of Biopsy-Confirmed Acute Rejection
Diagnosis of acute rejection was made via kidney biopsy using Banff criteria. Percentage of participants with biopsy-confirmed acute rejection was reported.
Time frame: Baseline up to Month 6
Histologic Grade of First Acute Rejection
Diagnosis of acute rejection was made via kidney biopsy. Categorization of biopsies with suspected acute rejection was based on histological findings using updated 1997 Banff criteria. Grade 1A: cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (5-10 cells/tubular cross section), Grade 1B: with severe tubulitis (\>10 cells/tubular cross section), Grade 2A: mild-moderate intimal arteritis, Grade 2B: severe intimal arteritis and Grade 3: transmural arterits and/or fibrinoid necrosis. Data is reported as percentage of participants.
Time frame: Baseline up to Month 12
Percentage of Participants Who Survived
Survival defined as participants living with or without a functioning graft.
Time frame: Month 12
Percentage of Participants With Graft Survival
Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.
Time frame: Month 12
Incidence of Presumptive or Documented Infection
Presumptive or documented infection during the 12 months after transplantation; was confirmed by culture, biopsy, or serology and reported. Percentage of participants with presumptive or documented infection was reported.
Time frame: Baseline up to Month 12
Incidence of Histologically Confirmed Lymphoproliferative Disease
Lymphoproliferative disorder represents an abnormal proliferation of B cells in response to either primary or reactivated infection with Epstein-Barr virus. Percentage of participants with histologically confirmed lymphoproliferative disease was reported.
Time frame: Baseline up to Month 12
Percentage of Participants With Efficacy Failure or Premature Elimination
Efficacy failure was defined as the first occurrence of acute rejection, graft loss, or death. Premature elimination was defined as elimination from the study for any other reason.
Time frame: Month 12
Incidence of Anemia
Diagnostic criterion for anemia was based on the laboratory results; in men: hemoglobin (Hb) \<14 gram per deciliter (g/dL), hematocrit (Hct) \<42%, or red blood cells (RBCs) \<4.5 million/liter (million/L); for women: Hb \<12 g/dL, Hct \<37%, or RBC \< 4 million/L. Percentage of participants with anaemia was reported.
Time frame: Baseline up to Month 12
Number of Participants Who Discontinued
Number of participants who discontinued the study treatment due to any reason is reported.
Time frame: Month 12
| Milestone | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Started | 125 | 120 |
| Completed | 96 | 91 |
| Not completed | 29 | 29 |
| Withdrew: Death | 2 | 5 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Lost to follow-up | 6 | 14 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Graft loss | 6 | 6 |
| Withdrew: Study events | 7 | 1 |
| Withdrew: Other | 5 | 1 |
Efficacy failure was defined as first occurrence of either biopsy confirmed acute rejection, graft loss or death within 12 months of post-transplantation. Percentage of participants with efficacy failure was reported.
| percentage of participants | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Incidence of Efficacy Failure | 11.4 | 13.5 |
Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 milligram per deciliter (mg/dL) for females and 0.6 to 1.2 mg/dL for males; however, the normal values are age-dependent as elderly patients typically have smaller muscle mass.
| mg/dL | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Month 3 (n=102, 94) | 1.4 ± 0.4 | 1.4 ± 0.4 |
| Month 6 (n=101, 92) | 1.2 ± 0.3 | 1.3 ± 0.4 |
| Month 12 (n=98, 91) | 1.2 ± 0.3 | 1.3 ± 0.3 |
Creatinine clearance (CCr) is a measure of kidney function. CCr is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Normal values for healthy, young males are in the range of 100-135 millimeters per minute (mL/min) and for females, 90-125 mL/min. Creatinine clearance decreases with age. A low creatinine clearance rate indicates poor kidney function.
| mL/min | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Month 3 (n=102, 94) | 64.0 ± 19.9 | 63.9 ± 16.0 |
| Month 6 (n=101, 92) | 72.8 ± 19.3 | 71.6 ± 18.3 |
| Month 12 (n=98, 91) | 76.4 ± 22.7 | 74.0 ± 28.6 |
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR was calculated using the Nankivell formula. GFR by Nankivell equation= (6.7 per serum creatinine) plus (0.25\*body weight) minus (0.5\*serum urea) minus (100 per height square) plus (35 for male or 25 for female). A normal GFR is greater than (\>)90 mL/min per 1.73 m\^2 \[mL/min/1.73 m\^2\], although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (\<)15 mL/min/1.73 m\^2 indicated kidney failure.
| mL/min/1.73 m^2 | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Month 3 (n=102, 94) | 59.5 ± 20.4 | 58.8 ± 15.2 |
| Month 6 (n=101, 92) | 65.2 ± 16.0 | 64.3 ± 19.5 |
| Month 12 (n=98, 91) | 67.4 ± 17.5 | 67.5 ± 46.5 |
Diagnosis of acute rejection was made via kidney biopsy using Banff criteria. Percentage of participants with biopsy-confirmed acute rejection was reported.
| percentage of participants | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Incidence of Biopsy-Confirmed Acute Rejection | 4.0 | 3.2 |
Diagnosis of acute rejection was made via kidney biopsy. Categorization of biopsies with suspected acute rejection was based on histological findings using updated 1997 Banff criteria. Grade 1A: cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (5-10 cells/tubular cross section), Grade 1B: with severe tubulitis (\>10 cells/tubular cross section), Grade 2A: mild-moderate intimal arteritis, Grade 2B: severe intimal arteritis and Grade 3: transmural arterits and/or fibrinoid necrosis. Data is reported as percentage of participants.
| percentage of participants | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| 1A | 100.0 | 66.7 |
| 1B | 0.0 | 33.3 |
Survival defined as participants living with or without a functioning graft.
| percentage of participants | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Percentage of Participants Who Survived | 98.0 | 94.8 |
Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.
| percentage of participants | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Percentage of Participants With Graft Survival | 94.1 | 93.8 |
Presumptive or documented infection during the 12 months after transplantation; was confirmed by culture, biopsy, or serology and reported. Percentage of participants with presumptive or documented infection was reported.
| percentage of participants | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Incidence of Presumptive or Documented Infection | 20.3 | 18.6 |
Lymphoproliferative disorder represents an abnormal proliferation of B cells in response to either primary or reactivated infection with Epstein-Barr virus. Percentage of participants with histologically confirmed lymphoproliferative disease was reported.
| percentage of participants | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Incidence of Histologically Confirmed Lymphoproliferative Disease | 1.0 | 0.0 |
Efficacy failure was defined as the first occurrence of acute rejection, graft loss, or death. Premature elimination was defined as elimination from the study for any other reason.
| percentage of participants | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Percentage of Participants With Efficacy Failure or Premature Elimination | 22.0 | 22.9 |
Diagnostic criterion for anemia was based on the laboratory results; in men: hemoglobin (Hb) \<14 gram per deciliter (g/dL), hematocrit (Hct) \<42%, or red blood cells (RBCs) \<4.5 million/liter (million/L); for women: Hb \<12 g/dL, Hct \<37%, or RBC \< 4 million/L. Percentage of participants with anaemia was reported.
| percentage of participants | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Incidence of Anemia | 94.3 | 98.3 |
Number of participants who discontinued the study treatment due to any reason is reported.
| participants | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Number of Participants Who Discontinued | 29 | 29 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CsA+Rapamune+CS | — | 56/125 (44.8%) | 67/125 (53.6%) |
| CsA+MMF+CS | — | 44/120 (36.7%) | 44/120 (36.7%) |
| Event | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Blood creatinine increasedInvestigations | 17/125 | 5/120 |
| Transplant rejectionImmune system disorders | 13/125 | 10/120 |
| Urinary tract infectionInfections and infestations | 8/125 | 3/120 |
| Therapeutic agent toxicityInjury, poisoning and procedural complications | 6/125 | 4/120 |
| Cytomegalovirus infectionInfections and infestations | 1/125 | 5/120 |
| Cytomegalovirus test positivInvestigations | 1/125 | 4/120 |
| LeukopeniaBlood and lymphatic system disorders | 4/125 | 1/120 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/125 | 1/120 |
| GastroenteritisGastrointestinal disorders | 4/125 | 1/120 |
| Wound infectionInfections and infestations | 4/125 | 1/120 |
| Event | CsA+Rapamune+CS | CsA+MMF+CS |
|---|---|---|
| Liver function test abnormalInvestigations | 21/125 | 8/120 |
| Blood triglycerides increasedInvestigations | 15/125 | 5/120 |
| Blood cholesterol increasedInvestigations | 11/125 | 3/120 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/125 | 0/120 |
| Alanine aminotransferase increasedInvestigations | 7/125 | 4/120 |
| Blood creatinine increasedInvestigations | 4/125 | 6/120 |
| Haemoglobin decreasedInvestigations | 6/125 | 6/120 |
| Blood glucose increasedInvestigations | 6/125 | 5/120 |
| Urinary tract infectionInfections and infestations | 4/125 | 5/120 |
| LeukopeniaBlood and lymphatic system disorders | 5/125 | 3/120 |
| Age, Continuous(years) | CsA+Rapamune+CS | CsA+MMF+CS | Total |
|---|---|---|---|
| Mean | 38.2 ± 13.4 | 41.6 ± 15.1 | 39.9 ± 14.3 |
| Sex: Female, Male(Participants) | CsA+Rapamune+CS | CsA+MMF+CS | Total |
|---|---|---|---|
| Female | 47 | 45 | 92 |
| Male | 78 | 75 | 153 |
The record gives a start of Apr 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 5 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclosporine · Mycophenolic Acid